Next Article in Journal
Increased Functional Foods’ Consumption and Mediterranean Diet Adherence May Have a Protective Effect in the Appearance of Gastrointestinal Diseases: A Case–Control Study
Next Article in Special Issue
Biological Potential and Medical Use of Secondary Metabolites
Previous Article in Journal
Phytochemical Modulation of MiRNAs in Colorectal Cancer
Previous Article in Special Issue
Semi-Synthesis and Evaluation of Sargahydroquinoic Acid Derivatives as Potential Antimalarial Agents
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle

In Vitro Evaluation of the Phytopharmacological Potential of Sargassum incisifolium for the Treatment of Inflammatory Bowel Diseases

1
Department of Biochemistry and Microbiology, P.O. Box 7700, Nelson Mandela University, Port Elizabeth 6031, South Africa
2
Faculty of Pharmacy, Division of Pharmaceutical Chemistry, P.O. Box 94, Rhodes University, Grahamstown 6140, South Africa
3
School of Pharmacy, Private Bag X17, University of the Western Cape, Bellville 7535, South Africa
*
Author to whom correspondence should be addressed.
Medicines 2019, 6(2), 49; https://doi.org/10.3390/medicines6020049
Received: 28 February 2019 / Revised: 20 March 2019 / Accepted: 28 March 2019 / Published: 6 April 2019
(This article belongs to the Special Issue Biological Potential and Medical Use of Secondary Metabolites)
  |  
PDF [2752 KB, uploaded 6 April 2019]
  |  

Abstract

Background: Comprised of Crohn’s disease and ulcerative colitis, inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the gastro-intestinal tract, which often results in severe damage to the intestinal mucosa. This study investigated metabolites from the South African endemic alga, Sargassum incisifolium, as potential treatments for IBD. Phytochemical evaluation of S. incisifolium yielded prenylated toluhydroquinones and toluquinones, from which semi-synthetic analogs were derived, and a carotenoid metabolite. The bioactivities of S. incisifolium fractions, natural products, and semi-synthetic derivatives were evaluated using various in vitro assays. Methods: Sargahydroquinoic acid isolated from S. incisifolium was converted to several structural derivatives by semi-synthetic modification. Potential modulation of IBD by S. incisifolium crude fractions, natural compounds, and sargahydroquinoic acid analogs was evaluated through in vitro anti-inflammatory activity, anti-oxidant activity, cytotoxicity against HT-29 and Caco-2 colorectal cancer cells, and PPAR-γ activation. Results: Sargahydroquinoic acid acts on various therapeutic targets relevant to IBD treatment. Conclusions: Conversion of sargahydroquinoic acid to sarganaphthoquinoic acid increases peroxisome proliferator activated receptor gamma (PPAR-γ) activity, compromises anti-oxidant activity, and has no effect on cytotoxicity against the tested cell lines. View Full-Text
Keywords: PPAR-γ; sargahydroquinoic acid; sarganaphthoquinoic acid; sargachromenoic acid; inflammation; bowel diseases PPAR-γ; sargahydroquinoic acid; sarganaphthoquinoic acid; sargachromenoic acid; inflammation; bowel diseases
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Nyambe, M.N.; Koekemoer, T.C.; van de Venter, M.; Goosen, E.D.; Beukes, D.R. In Vitro Evaluation of the Phytopharmacological Potential of Sargassum incisifolium for the Treatment of Inflammatory Bowel Diseases. Medicines 2019, 6, 49.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top